Homocysteine and ischaemic heart disease.
Law
M R
MR
Department of Environmental and Preventive Medicine, St, Bartholomew's Royal London School of Medicine and Dentistry, UK. m.r.law@mds.qmw.ac. uk
Wald
N J
NJ
D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / Q000172:deficiency / Q000235:genetics; D016022:Case-Control Studies; D015331:Cohort Studies; D015897:Comorbidity; D003541:Cystathionine beta-Synthase / Q000172:deficiency / Q000235:genetics; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000453:epidemiology; D008297:Male; D008715:Methionine / Q000378:metabolism; D008745:Methylation; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D017202:Myocardial Ischemia / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D016017:Odds Ratio; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000172:deficiency / Q000235:genetics; D012189:Retrospective Studies
D006710:Homocysteine; D005492:Folic Acid; D008715:Methionine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; D003541:Cystathionine beta-Synthase